Organization
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United States of America
5 abstracts
Abstract
A MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BARICITINIB, TARGETED SYNTHETIC OR BIOLOGIC DISEASE-MODIFYING THERAPIES (RA-BE-REAL) – STUDY DESIGN AND BASELINE CHARACTERISTICSOrg: University Medicine Berlin, Department of Internal Medicine and Rheumatology, Berlin, Germany, Charité Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, University of Florence, Division of Rheumatology, Florence, Italy, CHU de Reims, Traumatologie-Orthopédie, Reims, France, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United States of America,
Abstract
A MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BARICITINIB, TARGETED SYNTHETIC OR BIOLOGIC DISEASE-MODIFYING THERAPIES: 12 MONTH TIME TO DISCONTINUATION, EFFECTIVENESS AND PATIENT REPORTED OUTCOME DATA FROM THE EUROPEAN COHORTOrg: Schlosspark Klinik, Department of Internal Medicine and Rheumatology, Berlin, Germany, Charité Universitätsmedizin, Department of Rheumatology and Clinical Immunology, Indianapolis, United States of America, IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milan, Italy, University of Florence and Division of Rheumatology AOUC, Department of Experimental and Clinical Rheumatology, Florence, Italy, Monash University and Emeritus Research, Cabrini Hospital, Melbourne, Australia,
Abstract
A DEEP LEARNING METHOD UNCOVERS NOVEL PATHWAY ASSOCIATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUSOrg: Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Melbourne, Australia, DRFZ Berlin and Department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United States of America, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, United States of America,
Abstract
A 24-month Prospective Psoriatic Arthritis Observational Study of Persistence of Treatment (PRO-SPIRIT) - Interim Analysis of Baseline CharacteristicsOrg: University of Montpellier, Montpellier School of Medicine, Montpellier, France, CHU and University of Montpellier, Department of Rheumatology, Montpellier, France, IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR),, Milano, Italy, Vita-Salute San Raffaele University, /, Milano, Italy, Hospital Universitario, /, Madrid, Spain,
Abstract
BASELINE CHARACTERISTICS AND TREATMENT RESPONSE TO IXEKIZUMAB CATEGORISED BY SEX IN RADIOGRAPHIC AND NON-RADIOGRAPHIC AXIAL SPONDYLARTHRITIS PATIENTS THROUGH 52 WEEKS: DATA FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALSOrg: Amsterdam UMC, locatie VUmc, Department of Rheumatology, Amsterdam, Netherlands, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United States of America, MetroHealth, Rhematology Department, Cleveland, United States of America,